“EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence ”, J. Can. Res. Updates, vol. 1, no. 1, pp.  102–107, Jan. 2012, doi: 10.6000/1929-2279.2012.01.01.15.